Patent application number | Description | Published |
20100038601 | DURABLE TRANSPARENT CONDUCTORS ON POLYMERIC SUBSTRATES - A method of preparing a transparent conductor for application on a polymeric substrate is described. The method includes introducing a functional group onto a surface of the conductor to form a modified conductor, and mixing the modified conductor with a dispersant at slightly elevated temperatures to form a conductive material composition. The dispersant is at least bifunctional. The conductive material composition may then be applied to the polymeric substrate. The dispersant acts as a linker, bonding the transparent conductor and polymeric substrate such that they are fully integrated. | 02-18-2010 |
20100273095 | METHOD OF COATING A SURFACE OF A FUEL CELL PLATE - A method of coating a surface of a fuel cell plate is disclosed herein. The method involves forming a sol gel mixture including a metal oxide modified with at least one functional group, where the at least one functional group is configured to improve adhesion; and adding carbon modified with a hydrophilic functional group to the mixture, thereby forming a suspension. The suspension is applied to the surface of the fuel cell plate, and is activated to form a porous, hydrophilic, and conductive film on the surface of the fuel cell plate. | 10-28-2010 |
20130272953 | METHOD FOR MANUFACTURING INDIUM TIN OXIDE NANOWIRES - A method for manufacturing indium tin oxide nanowires by preparing a solution that includes an indium-containing species, a tin-containing species and a polymeric material, wherein the solution has a molar ratio of tin to indium in a range from about 5 to about 15 percent, electrospinning fibers using the solution, and heating the fibers to a calcination temperature and maintaining the fibers at the calcination temperature for a predetermined calcination time. | 10-17-2013 |
20130331509 | Flexible, Low Temperature, Filled Composite Material Compositions, Coatings, and Methods - There is provided a flexible, low temperature, filled composite material composition and method of synthesizing the composite material composition. The composite material composition has a segmented copolymer elastomer having an α,ω-(alpha, omega)-dihydroxy terminated polysiloxane species, a diisocyanate species, and an amine or hydroxy terminated chain extender. The composite material composition further has a solid particulate filler. The composite material composition has a high flexibility at a temperature of down to about −100 degrees Celsius, has a percent elongation of greater than about 100%, and has a tensile strength of greater than about 5 MPa (megapascals). | 12-12-2013 |
Patent application number | Description | Published |
20080261342 | Chemical Sensor Using Semiconducting Metal Oxide Nanowires - Indium oxide nanowires are used for determining information about different chemicals or Biologics. Chemicals are absorbed to the surface of the nanowires, and cause the semiconducting characteristics of the Nanowires to change. These changed characteristics are sensed, and used to determine either the presence of the materials and/or the concentration of the materials. The nanowires may be between 10 and 30 nm in diameter, formed using a comparable size particle of catalyst material. The nanowires may then be used as part of the channel of a field effect transistor, and the field effect transistor is itself characterized. | 10-23-2008 |
20100204062 | CALIBRATION METHODS FOR MULTIPLEXED SENSOR ARRAYS - The present invention relates to the calibration of devices using a secondary binding agent or reference material. In one embodiment, the present invention provides a method of calibrating a nanosensor by providing a nanosensor comprising an analyte binder attached to a reference binder, extracting a calibration curve from binding a reference material to the reference binder, and calibrating the nanosensor by using the calibration curve to correct for device variation. | 08-12-2010 |
20110017975 | ORGANIC OPTOELECTRONIC DEVICE ELECTRODES WITH NANOTUBES - An electrode for use in an organic optoelectronic device is provided. The electrode includes a thin film of single-wall carbon nanotubes. The film may be deposited on a substrate of the device by using an elastomeric stamp. The film may be enhanced by spin-coating a smoothing layer on the film and/or doping the film to enhance conductivity. Electrodes according to the present invention may have conductivities, transparencies, and other features comparable to other materials typically used as electrodes in optoelectronic devices. | 01-27-2011 |
20130059406 | ORGANIC OPTOELECTRONIC DEVICE ELECTRODES WITH NANOTUBES - An electrode for use in an organic optoelectronic device is provided. The electrode includes a thin film of single-wall carbon nanotubes. The film may be deposited on a substrate of the device by using an elastomeric stamp. The film may be enhanced by spin-coating a smoothing layer on the film and/or doping the film to enhance conductivity. Electrodes according to the present invention may have conductivities, transparencies, and other features comparable to other materials typically used as electrodes in optoelectronic devices. | 03-07-2013 |
Patent application number | Description | Published |
20080254745 | SYSTEMS AND METHODS FOR PROVIDING COLLABORATIVE COEXISTENCE BETWEEN BLUETOOTH AND WI-FI - Methods and systems are described for providing Bluetooth and Wi-Fi coexistence on an electronic device. Aspects of exemplary embodiments include determining Bluetooth link parameters for a Bluetooth connection and Wi-Fi link parameters for a Wi-Fi connection. Also, a Bluetooth path loss for the Bluetooth connection and a Wi-Fi path loss for the Wi-Fi connection can be determined. According to this embodiment, one or more link conditions, based upon one or more of the Bluetooth link parameters, the Wi-Fi link parameters, the Bluetooth path loss, and the Wi-Fi path loss, may be calculated to determine if simultaneous collaboration between the Bluetooth connection and Wi-Fi connection is feasible. In response to simultaneous collaboration being feasible, the Bluetooth link parameters and the Wi-Fi link parameters are customized based on the one or more link conditions to permit simultaneous collaboration between the Bluetooth connection and the Wi-Fi connection. | 10-16-2008 |
20130179378 | Knowledge Reasoning Method of Boolean Satisfiability (SAT) - Disclosed is a knowledge reasoning method for solving Boolean Satisfiability problems. This method is one of the applications of the method disclosed in the US patent “Knowledge Acquisition and Retrieval Apparatus and Method” (U.S. Pat. No. 6,611,841). Disclosed method applies learning function to access iterative set relations among variables, literals, words and clauses as knowledge; And applies deduction and reduction functions to retrieve relations as reasoning. The process is a knowledge learning (KL) and knowledge reasoning algorithm (KRA). KRA abandons the “OR” operation of Boolean logic and processes only set relations of the data. The novelty of the disclosed method is the reversibility between the deduction and reduction. That is, KRA of Boolean Satisfiability applies a pair of perceptual-conceptual languages to learn member-class relations and retrieve information through deductive and reductive reasoning. | 07-11-2013 |
20140289181 | Knowledge Reasoning Method of Boolean Satisfiability (SAT) - Disclosed is a knowledge reasoning method for solving Boolean Satisfiability problems. This method is one of the applications of the method disclosed in the US patent “Knowledge Acquisition and Retrieval Apparatus and Method” (U.S. Pat. No. 6,611,841). Disclosed method applies learning function to access iterative set relations among variables, literals, words and clauses as knowledge; And applies deduction and reduction functions to retrieve relations as reasoning. The process is a knowledge learning (KL) and knowledge reasoning algorithm (KRA). KRA abandons the “OR” operation of Boolean logic and processes only set relations of the data. The novelty of the disclosed method is the reversibility between the deduction and reduction. That is, KRA of Boolean Satisfiability applies a pair of perceptual-conceptual languages to learn member-class relations and retrieve information through deductive and reductive reasoning. | 09-25-2014 |
Patent application number | Description | Published |
20090118805 | Return Electrode for a Flexible Circuit Electrode Array - In a visual prosthesis electrodes stimulate retinal tissue to induce the perception of light to a user implanted with the prosthesis. The prosthesis must have a return, or common, electrode to make a complete circuit with the retinal tissue. To avoid stimulating tissue with the return electrode, it is advantageous if the electrode is large. | 05-07-2009 |
20090143848 | Cochlear Stimulation Device - A cochlear stimulation device comprising an electrode array designed to provide enhanced charge injection capacity necessary for neural stimulation. The electrode array comprises electrodes with high surface area or a fractal geometry and correspondingly high electrode capacitance and low electrical impedance. The resultant electrodes have a robust surface and sufficient mechanical strength to withstand physical stress vital for long term stability. The device further comprises wire traces having a multilayer structure which provides a reduced width for the conducting part of the electrode array. The cochlear prosthesis is attached by a grommet to the cochleostomy that is made from a single piece of biocompatible polymer. The device, designed to achieve optimum neural stimulation by appropriate electrode design, is a significant improvement over commercially available hand-built devices. | 06-04-2009 |
20090264972 | Flexible Circuit Electrode Array - A flexible circuit electrode array, which comprises: a polymer base layer; metal traces deposited on said polymer base layer, including electrodes suitable to stimulate neural tissue; a polymer top layer deposited on said polymer base layer and said metal traces; and a partial or entire coating of the base and top layer by a soft polymer. | 10-22-2009 |
20110270067 | Biocompatible Bonding Method - The invention is a device and method for connecting a hermetic package to a flexible circuit such as for an electrode array in an implantable device. Attaching metal pads on a flexible circuit to metal pads on a hermetic device by conductive adhesive is known. A smooth metal, such as platinum, does not bond well to conductive epoxy. The invention provides a roughened surface, such as etching or applying high surface area platinum gray, to improve adhesion to platinum or other metal pads. | 11-03-2011 |
20120239126 | Visual Prosthesis Including a Flexible Circuit Electrode Array - A visual prosthesis which includes a hermetic package and flexible circuit electrode array is disclosed. The hermetic package includes electrode drivers and contacts. The flexible circuit electrode array includes a polymer base layer, metal traces, including electrodes suitable to stimulate visual neural tissue and bond pads bonded to contacts on the hermetic package, all deposited on the polymer base layer, a polymer top layer deposited on the polymer base layer and deposited on the metal traces, a partial or an entire coating of the polymer base layer and of the polymer top layer by a soft polymer that is softer than the polymer base layer; and the polymer base layer and the polymer top layer contain a plurality of aligned holes to facilitate bonding of the soft polymer. | 09-20-2012 |
20120296444 | Cortical Interface for Motor Signal Recording and Sensory Signal Stimulation - The present invention consists of an implantable device with at least one package that houses electronics that sends and receives data or signals, and optionally power, from an external system through at least one coil attached to the at least one package and processes the data, including recordings of neural activity, and delivers electrical pulses to neural tissue through at least one array of multiple electrodes that is/are attached to the at least one package. The device is adapted to electrocorticographic (ECoG) and local field potential (LFP) signals. The output signals provide control for a motor prosthesis and the inputs signals provide sensory feedback for the motor prosthesis. The invention, or components thereof, is/are intended to be installed in the head, or on or in the cranium or on the dura, or on or in the brain. | 11-22-2012 |
20130143148 | Fuel Cell with an Improved Electrode - An improved platinum and method for manufacturing the improved platinum wherein the platinum having a fractal surface coating of platinum, platinum gray, with a increase in surface area of at least 5 times when compared to shiny platinum of the same geometry and also having improved resistance to physical stress when compared to platinum black having the same surface area. The process of electroplating the surface coating of platinum gray comprising plating at a moderate rate, for example at a rate that is faster than the rate necessary to produce shiny platinum and that is less than the rate necessary to produce platinum black. Platinum gray is applied to manufacture a fuel cell and a catalyst. | 06-06-2013 |
20140074210 | High-Density Array of Micro-machined Electrodes for Neural Stimulation - The present invention is a micro-machined electrode for neural-electronic interfaces which can achieve a ten times lower impedance and higher charge injection limit for a given material and planar area. | 03-13-2014 |
20140222103 | Cortical Visual Prosthesis - The present invention is a visual prosthesis adapted for implantation in the brain, and more particularly with an electrode array adapted for implantation in the Calcarine Sulcus of the visual cortex. The electrode array of the invention has electrodes on each side and spaced appropriately for the Calcarine Sulcus and driven by an electronic circuit within a hermetic package small enough to be implanted with a skull. | 08-07-2014 |
20140327460 | Test Apparatus and Method for Determining Long Term Reliability of an Implantable Device - The present invention is a system and method for testing the long term reliability of an implantable device. The system provides a vessel containing temperature controlled buffered saline. A support structure suspends a test device in the vessel so it is submerged in the buffered saline and provides mechanical stress on the implantable devices. The test device is eclectically connected to a programmable signal generator and sensors to actively determine the integrity of the device during active testing. | 11-06-2014 |
Patent application number | Description | Published |
20080229442 | NUCLEOTIDE SEQUENCES AND CORRESPONDING POLYPEPTIDES CONFERRING MODULATED GROWTH RATE AND BIOMASS IN PLANTS GROWN IN SALINE AND OXIDATIVE CONDITIONS - The present invention related to isolated nucleic acid molecules and their corresponding encoded polypeptides able confer the trait of improved plant size, vegetative growth, growth rate seedling vigor and/or biomass in plants challenged with saline and/or oxidative stress conditions. The present invention further relates to the use of these nucleic acid molecules and polypeptides in making transgenic plants, plant cells, plant materials or seeds of a plant having plant size, vegetative growth, growth rate, seedling vigor and/or biomass that are improved in saline and/or oxidative stress conditions with respect to wild-type plants grown under similar conditions. | 09-18-2008 |
20090100539 | NUCLEOTIDE SEQUENCES AND CORRESPONDING POLYPEPTIDES CONFERRING MODULATED GROWTH RATE AND BIOMASS IN PLANTS GROWN IN SALINE CONDITIONS - The present invention relates to isolated nucleic acid molecules and their corresponding encoded polypeptides able confer the trait of improved plant size, vegetative growth, growth rate, seedling vigor and/or biomass in plants challenged with saline conditions. The present invention further relates to the use of these nucleic acid molecules and polypeptides in making transgenic plants, plant cells, plant materials or seeds of a plant having plant size, vegetative growth, growth rate, seedling vigor and/or biomass that are improved in saline conditions with respect to wild-type plants grown under similar conditions | 04-16-2009 |
20110265199 | NUCLEOTIDE SEQUENCES AND POLYPEPTIDES ENCODED THEREBY USEFUL FOR INCREASING TOLERANCE TO OXIDATIVE STRESS IN PLANTS - The present invention relates to isolated nucleic acid molecules and their corresponding encoded polypeptides able confer the trait of improved plant size, vegetative growth, growth rate, seedling vigor and/or biomass in plants challenged with oxidative stress conditions. The present invention further relates to the use of these nucleic acid molecules and polypeptides in making transgenic plants, plant cells, plant materials or seeds of a plant having plant size, vegetative growth, growth rate, seedling vigor and/or biomass that are improved in oxidative stress conditions with respect to wild-type plants grown under similar conditions. | 10-27-2011 |
20120227123 | NUCLEOTIDE SEQUENCES AND CORRESPONDING POLYPEPTIDES CONFERRING MODULATED GROWTH RATE AND BIOMASS IN PLANTS GROWN IN SALINE AND OXIDATIVE CONDITIONS - The present invention relates to isolated nucleic acid molecules and their corresponding encoded polypeptides able confer the trait of improved plant size, vegetative growth, growth rate, seedling vigor and/or biomass in plants challenged with saline and/or oxidative stress conditions. The present invention further relates to the use of these nucleic acid molecules and polypeptides in making transgenic plants, plant cells, plant materials or seeds of a plant having plant size, vegetative growth, growth rate, seedling vigor and/or biomass that are improved in saline and/or oxidative stress conditions with respect to wild-type plants grown under similar conditions. | 09-06-2012 |
20130042367 | NUCLEOTIDE SEQUENCES AND CORRESPONDING POLYPEPTIDES CONFERRING MODIFIED PHENOTYPE CHARACTERISTICS IN PLANTS - Methods and materials for modulating low-nitrogen tolerance levels in plants are disclosed. For example, nucleic acids encoding low nitrogen tolerance-modulating polypeptides are disclosed as well as methods for using such nucleic acids to transform plant cells. Also disclosed are plants having increased | 02-14-2013 |
20130160163 | NUCLEOTIDE SEQUENCES AND CORRESPONDING POLYPEPTIDES CONFERRING MODULATED GROWTH RATE AND BIOMASS IN PLANTS GROWN IN SALINE CONDITIONS - The present invention relates to isolated nucleic acid molecules and their corresponding encoded polypeptides able confer the trait of improved plant size, vegetative growth, growth rate, seedling vigor and/or biomass in plants challenged with saline conditions. The present invention further relates to the use of these nucleic acid molecules and polypeptides in making transgenic plants, plant cells, plant materials or seeds of a plant having plant size, vegetative growth, growth rate, seedling vigor and/or biomass that are improved in saline conditions with respect to wild-type plants grown under similar conditions. | 06-20-2013 |
Patent application number | Description | Published |
20090036086 | REDUCING SPECTRAL ROLL-OFF FACTORS TO INCREASE SPECTRAL EFFICIENCY - Systems for delivering a plurality of broadcast programs where the transmitter and receiver roll-off factors are mismatched. A system in accordance with the present invention comprises a transmitter comprising a modulator, and a plurality of receivers, each receiver in the plurality of receivers receiving the plurality of broadcast programs, each receiver in the plurality of receivers further comprising a demodulator; wherein the modulator has a first root-raised cosine filter having a first roll-off factor and each receiver has a second root-raised cosine filter having a second roll-off factor, the first roll-off factor being smaller than the second roll-off factor. | 02-05-2009 |
20090052503 | SHIFTED CHANNEL CHARACTERISTICS FOR MITIGATING CO-CHANNEL INTERFERENCE - Methods and apparatuses for minimizing co-channel interference in communications systems are disclosed. A method in accordance with the present invention comprises shifting a characteristic of the first signal with respect to a like characteristic of the second signal to mitigate co-channel interference, and transmitting the first signal and the second signal over different channels of the communication system. | 02-26-2009 |
20090068953 | METHODS AND APPARATUSES FOR MINIMIZING CO-CHANNEL INTERFERENCE - Methods and apparatuses for minimizing co-channel interference in communications systems are disclosed. A method in accordance with the present invention comprises scrambling a first frame using a first scrambling code, attaching a first header to the first frame to create the first signal, scrambling a second frame using a second scrambling code, attaching a second header to the second frame to create the second signal, and transmitting the first signal and the second signal over different channels of the communication system. | 03-12-2009 |
20100157881 | BLIND IDENTIFICATION OF ADVANCED MODULATION AND CODING MODES - Methods and apparatuses for acquiring and demodulating a data stream transmitted in a communication system. A method in accordance with the present invention comprises finding a boundary of a physical layer frame (PLFrame) in the data stream, finding a first 26 bits of a Unique Word (UW) associated with the data stream, finding a scrambling code utilizing the UW, and using a decoding procedure to determine a modulation type and code rate used for desired signals within the data stream. | 06-24-2010 |
20110080517 | PHASE NOISE AND FREQUENCY ERROR RESILIENT DEMODULATION SCHEME FOR MOCA - Systems and methods for demodulating signals are disclosed. A system in accordance with the present invention comprises a frequency estimator, a tuner, coupled to the frequency estimator, for tuning to a frequency based on an estimate from the frequency estimator, a phase offset estimator for determining an average phase offset, and a demodulator, coupled to the tuner and the phase offset estimator, for demodulating the plurality of symbols, wherein the demodulator corrects a phase offset for a given symbol in the plurality of the symbols based on the average phase offset of symbols prior to the given symbol. | 04-07-2011 |
20120257697 | METHOD AND APPARATUS FOR IDENTIFYING CO-CHANNEL INTERFERENCE - Methods and apparatuses identifying a co-channel interference signal in communications systems are disclosed. An exemplary method comprises generating an interference signal by subtracting a reconstructed desired signal from an at least partially demodulated composite signal, and generating synchronization statistics of interference signal using different scrambling codes. The interference signal is identified as the signal associated with the scrambling code that was used to generate an interference signal having a desired synchronization statistic. | 10-11-2012 |
20130101007 | Systems and Methods for Channel Estimation of MoCA Signals - Systems and methods are provided, for estimating a channel based on previous channel estimations from the same source. Embodiments disclosed herein enable removal of the timing variation (from burst to burst) so that the channel can be more accurately estimated. Embodiments provide several systems and methods for averaging channel estimation information from each of the bursts. The systems and methods disclosed herein advantageously improve channel estimation accuracy and reduce modulation error. | 04-25-2013 |
20130235887 | CHANNEL BONDING SYNCHRONIZATION - Different data communication architectures deliver a wide variety of content, including audio and video content, to consumers. The architectures employ channel bonding to deliver more bandwidth than any single communication channel can carry. In some implementations, the communication architectures distribute data streams to bonded channels that are clocked independently. A system is provided for synchronizing the bonded channels. | 09-12-2013 |
20130239160 | Cross Layer Coordinated Channel Bonding - Different data communication architectures deliver a wide variety of content, including audio and video content, to consumers. The architectures employ channel bonding to deliver more bandwidth than any single communication channel can carry. In some implementations, the communication architectures distribute video programming in the form of MPEG2 TS packets, flagged by marker packets, in a round-robin manner across the communication channels. Channel bonding synchronization information may be present in packets defined above the data-link layer or added to fields within data-link layer frames. | 09-12-2013 |
20140173672 | Cross Layer Coordinated Channel Bonding - Different data communication architectures receive a wide variety of content, including audio and video content, for consumers. The architectures employ channel bonding to deliver more bandwidth than any single communication channel can carry. In some implementations, the communication architectures receive distributed video programming in the form of MPEG2 TS packets, flagged by marker packets. Channel bonding synchronization information may be present in packets defined above the data-link layer or received in fields within data-link layer frames. | 06-19-2014 |
Patent application number | Description | Published |
20100077651 | BIODIESEL-DERIVED COMBUSTION IMPROVER - The present invention is generally directed to novel fuel compositions and to methods (i.e., processes) for enhancing the combustion efficiency and/or other properties of diesel fuels, particularly wherein such diesel fuels are, or comprise, biodiesel, such biodiesel typically having poorer low-temperature properties than traditional (petroleum) diesel. Generally, such fuel compositions are provided by the creation and inclusion of a quantity of one or more epoxy-ester species, such species serving as combustion improvers for the fuel composition of which they are part. | 04-01-2010 |
20100154291 | METHODS FOR IMPROVING LOW-TEMPERATURE PROPERTIES OF BIODIESEL FUEL - The present invention is generally directed to novel biodiesel fuel compositions having enhanced low-temperature properties. The present invention is additionally directed to methods (i.e., processes) for making such enhanced biodiesel fuels by improving the low-temperature properties of ester-based biodiesel fuels via in situ enhancement and/or additive enhancement. | 06-24-2010 |
20100154292 | ENHANCED BIODIESEL FUEL HAVING IMPROVED LOW-TEMPERATURE PROPERTIES AND METHODS OF MAKING SAME - The present invention is generally directed to novel biodiesel fuel compositions having enhanced low-temperature properties. The present invention is additionally directed to methods (i.e., processes) for making such enhanced biodiesel fuels by improving the low-temperature properties of ester-based biodiesel fuels via in situ enhancement and/or additive enhancement. | 06-24-2010 |
20110203165 | ENHANCED BIODIESEL FUEL HAVING IMPROVED LOW-TEMPERATURE PROPERTIES AND METHODS OF MAKING SAME - The present invention is generally directed to novel biodiesel fuel compositions having enhanced low-temperature properties. The present invention is additionally directed to methods (i.e., processes) for making such enhanced biodiesel fuels by improving the low-temperature properties of ester-based biodiesel fuels via in situ enhancement and/or additive enhancement. | 08-25-2011 |
20120283491 | Low Pour Point Renewable Fuel Blend - A renewable fuel blend and a process for producing a renewable fuel blend are described. The blend includes biologically derived C | 11-08-2012 |
20140058147 | Process For Production Of Distillate Fuel - The present invention is directed to preparing distillate fuel having almost no oxygen and no carbon-to-carbon double bonds. The method comprises passing biodiesel and/or lipids derived from vegetable oils, algae oils, and/or animal fats over bio-feedstock, or lipids, conversion catalyst that performs the hydrocarbon isomerization function, removes oxygen from the feedstock, cracks off the C | 02-27-2014 |
20140058148 | Process For Production Of Distillate Fuel - The present invention is directed to preparing distillate fuel having almost no oxygen and no carbon-to-carbon double bonds. The method comprises passing biodiesel and/or lipids derived from vegetable oils, algae oils, and/or animal fats over a bio-feedstock, or lipids, conversion catalyst that performs the hydrocarbon isomerization function, removes oxygen from the feedstock, cracks off the C | 02-27-2014 |
Patent application number | Description | Published |
20080312310 | Compounds, Compositions and Methods - Compounds, compositions and methods useful for treating cellular proliferative diseases and disorders, for example, by modulating the activity of KSP, are disclosed. | 12-18-2008 |
20090203698 | Compounds for Enzyme Inhibition - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles. | 08-13-2009 |
20100144648 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 06-10-2010 |
20100144649 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 06-10-2010 |
20110288082 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE - Compounds of Formulas I-XLIII are identified as direct inhibitors of p97 ATPase or of the degradation of a p97-dependent ubiquitin-proteasome system (UPS) substrate. Methods and compositions are disclosed for inhibiting p97 ATPase and the degradation of a p97-dependent UPS substrate, and for identifying inhibitors thereof | 11-24-2011 |
20120088762 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 04-12-2012 |
20130035297 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 02-07-2013 |
20130041008 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 02-14-2013 |
20130130968 | COMPOUNDS FOR ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles. | 05-23-2013 |
20130338057 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 12-19-2013 |
20140024661 | FUSED PYRIMIDINES AND SUBSTITUTED QUINAZOLINES AS INHIBITORS OF P97 - A group of fused two ring pyrimidine compounds having a heterocycles substituent at the 2 position and a substituted amine at the 4 position as well as optional aliphatic, functional and/or aromatic components substituted at other positions of the pyrimidine and other ring are disclosed. In addition a group of quinazoline compounds having similar substituents at the 2 and 4 positions as well as at other positions are disclosed. These compounds are inhibitors of the AAA proteasome complex containing p97 and are effective medicinal agents for treatment of diseases associated with p97 bioactivity. | 01-23-2014 |
20140031297 | COMPOUNDS FOR ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles. | 01-30-2014 |
20140050737 | COMPOUNDS FOR ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles. | 02-20-2014 |
20140051641 | COMPOUNDS FOR ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles. | 02-20-2014 |
20140080753 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 03-20-2014 |
20140100169 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 04-10-2014 |
20140235548 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION - Compounds, pharmaceutical compositions, and methods of using such compounds to treat or prevent diseases or disorders associated with or mediated by JAMM proteins are disclosed. The compounds and compositions inhibit the enzymatic activity of a JAMM domain, including the JAMM domain of the CSN5 subunit of the COP9-signalsome (CSN), the JAMM domain of the Rpn11/Poh1/Psmd14 subunit of the 26S proteasome, the JAMM domain of AMSH, the JAMM domain of AMSH-LP, the JAMM domain of BRCC36, among other JAMM domains. | 08-21-2014 |
Patent application number | Description | Published |
20100111747 | Exploitation of Deformation Mechanisms for Industrial Usage in Thin Product Forms - The present disclosure relates to a glass forming alloy. The glass forming alloy may include 43.0 atomic percent to 68.0 atomic percent iron, 10.0 atomic percent to 19.0 atomic percent boron, 13.0 atomic percent to 17.0 atomic percent nickel, 2.5 atomic percent to 21.0 atomic percent cobalt, optionally 0.1 atomic percent to 6.0 atomic percent carbon, and optionally 0.3 atomic percent to 3.5 atomic percent silicon. Furthermore, the glass forming alloy includes between 5% to 95% by volume one or more spinodal glass matrix microconstituents which include one or more semi-crystalline or crystalline phases at a length scale less than 50 nm in a glass matrix. In addition, the glass forming alloy is capable of blunting shear bands through localized deformation induced changes under tension. | 05-06-2010 |
20110094700 | Process For Continuous Production Of Ductile Microwires From Glass Forming Systems - A method and system of forming a micro-wire including heating metal feedstock to a liquid state within a glass tube, wherein the metal feedstock includes an iron based glass forming alloy comprising one or more of nickel and cobalt present in the range of 7 atomic percent to 50 atomic percent and one or more of boron, carbon, silicon, phosphorous and nitrogen present in the range of 1 to 35 atomic percent. Negative pressure may be provided to the interior the glass tube and the glass tube containing the metal feedstock may be drawn down. The metal feedstock in the glass tube may be cooled at a rate sufficient to form a wire exhibiting crystalline microstructures present in the range of 2 to 90 percent by volume in a glass matrix. | 04-28-2011 |
20110100347 | Wire and Methodology for Cutting Materials With Wire - Wire for cutting feedstock and a method for cutting feedstock with the wire. The wire may include an iron based alloy comprising at least 35 at % iron, nickel and/or cobalt in the range of about 7 to 50 at %, at least one non-metal or metalloid selected from the group consisting of boron, carbon, silicon, phosphorus, and/or nitrogen present in the range of about 1 to 35 at %, and one metal selected from the group consisting of copper, titanium, molybdenum, aluminum, and/or chromium present in the range of about 0 to 25 at %, wherein the wire has an aspect ratio of greater than one and exhibits metallic and/or crystalline phases of less than 500 nm in size. | 05-05-2011 |
20110108166 | Utilization of Amorphous Steel Sheets In Honeycomb Structures - A honeycomb structure and a method of forming an iron based glass forming honeycomb structure. The honeycomb structure may include at least two sheets, each having a thickness in the range of 0.01 mm to 0.15 mm, formed from an iron based glass forming alloy comprising 40 to 68 atomic percent iron, 13 to 17 atomic percent nickel, 2 to 21 atomic percent cobalt, 12 to 19 atomic percent boron, optionally 0.1 to 6 atomic percent carbon, optionally 0.3 to 4 atomic percent silicon, optionally 1 to 20 percent chromium. The sheets may be stacked, bonded together and formed into a honeycomb. The honeycomb structure may include a plurality of cells. | 05-12-2011 |
20110186259 | Utilization of Carbon Dioxide And/Or Carbon Monoxide Gases in Processing Metallic Glass Compositions - A method of forming an iron based glass forming alloy. The method may include providing a feedstock of an iron based glass forming alloy, melting the feedstock, casting the feedstock into an elongated body in an environment comprising 50% or more of a gas selected from carbon dioxide, carbon monoxide or mixtures thereof. | 08-04-2011 |
20110293463 | ALLOYS EXHIBITING SPINODAL GLASS MATRIX MICROCONSTITUENTS STRUCTURE AND DEFORMATION MECHANISMS - An alloy composition comprising iron present in the range of 49 atomic percent (at %) to 65 at %, nickel present in the range of 10.0 at % to 16.5 at %, cobalt optionally present in the range of 0.1 at % to 12 at %, boron present in the range of 12.5 at % to 16.5 at %, silicon optionally present in the range of 0.1 at % to 8.0 at %, carbon optionally present in the range of 2 at % to 5 at %, chromium optionally present in the range of 2.5 at % to 13.35 at %, and niobium optionally present in the range of 1.5 at % to 2.5 at %, wherein the alloy composition exhibits spinodal glass matrix microconstituents when cooled at a rate in the range of 10 | 12-01-2011 |
Patent application number | Description | Published |
20090081182 | Modified Lecithin-Cholesterol Acyltransferase Enzymes - The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, coronary heart disease, thrombosis, and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide. | 03-26-2009 |
20110206652 | METHODS FOR TREATING ATHEROSCLEROSIS - The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, inflammation, thrombosis and other conditions and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide. | 08-25-2011 |
20130273024 | METHODS FOR TREATING ATHEROSCLEROSIS - The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, inflammation, thrombosis and other conditions and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide. | 10-17-2013 |
20140287479 | MODIFIED LECITHIN-CHOLESTEROL ACYLTRANSFERASE ENZYMES - The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, coronary heart disease, thrombosis, and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide. | 09-25-2014 |
Patent application number | Description | Published |
20080312552 | Method to detect change in tissue measurements - The present invention relates to the detection of statistically significant changes in tissue characteristics within the eye. Change in a tissue characteristic is statistically significant when the magnitude of the change exceeds the test-retest measurement variability. One embodiment of the present invention analyzes the data using more than one statistic in order to capture global, regional, and/or local changes that are essential to clinical interpretation of changes in a tissue characteristic. In one embodiment of the present invention, the tissue characteristic tested is RNFL thickness. | 12-18-2008 |
20110190657 | GLAUCOMA COMBINATORIAL ANALYSIS - The subject invention relates to combinatorial analyses of data from two or more diagnostic tests for the detection of eye diseases, simplified interpretation of test results, and assessment of disease stage and rate of change. Of particular interest is to develop combinatorial analyses to improve glaucoma detection and progression rate assessment based on combinations of structural and functional tests. More specifically, approaches are described where data of one or more tests and their normative database are converted to the distribution and scale of another test for further analysis to detect glaucomatous damage; approaches are also described where data of more than one tests are used to assess stage index and rate of change; in addition, methods for displaying the combinatorial analysis results are disclosed. | 08-04-2011 |
20120140174 | SCANNING AND PROCESSING USING OPTICAL COHERENCE TOMOGRAPHY - In accordance with some embodiments, a method of eye examination includes acquiring OCT data with a scan pattern centered on an eye cornea that includes n radial scans repeated r times, c circular scans repeated r times, and n* raster scans where the scan pattern is repeated m times, where each scan includes a A-scans, and where n is an integer that is 0 or greater, r is an integer that is 1 or greater, c is an integer that is 0 or greater, n* is an integer that is 0 or greater, m is an integer that is 1 or greater, and a is an integer greater than 1, the values of n, r, c, n*, and m being chosen to provide OCT data for a target measurement, and processing the OCT data to obtain the target measurement. | 06-07-2012 |
Patent application number | Description | Published |
20090253119 | LATERAL FLOW SYSTEM AND ASSAY - The present invention relates to a lateral flow assay and system, including a test strip, for detection and quantification of analytes in samples, such as samples containing cells and fluid. In general, according to the present invention, a test strip for a lateral flow assay for detection of at least one analyte in a sample comprises: (1) a chromatographic strip, a sample filter, a fluid-impermeable barrier, and means for providing a mobilizable detectable agent that is capable of binding to the at least one analyte or to the capture agent after capturing the analyte to the chromatographic strip such that the mobilizable detectable agent migrates through the chromatographic strip and contacts sample that has passed through the sample filter and also has migrated through the chromatographic strip. The test strip allows detection with or without quantitation of an analyte in a sample containing whole cells. | 10-08-2009 |
20100092945 | TEST STRIP FOR A LATERAL FLOW ASSAY FOR A SAMPLE CONTAINING WHOLE CELLS - A test strip for conducting a lateral flow assay for detection of an analyte in a sample that contains cells and fluid is provided, as well as methods for making and using the test strip. This test strip is commercially usable, for example, in a diagnostic device at a point of care for detection of analytes in whole blood. | 04-15-2010 |
20100099112 | QUANTITATIVE LATERAL FLOW SYSTEM AND ASSAY - The present invention relates to a lateral flow assay and system, including a test strip, for detection and quantification of analytes in samples, such as samples containing cells and fluid, where the assay is volume independent, and the sample size is less than about 100 μl, where the test strip includes a first membrane such as a sample filter, that is in capillary contact with an optional second membrane, such as a fluid collector, the second membrane, if present is in capillary contact with an optional third membrane, such as a conjugate pad containing a mobilizable detectable agent, or with a fourth membrane, which is a chromatographic strip, which optionally contains a mobilizable detectable agent, all such membranes being in fluid contact with a fifth membrane, such as a buffer pad, a sixth membrane, such as an absorbent pad, optionally a seventh membrane, which is also an absorbent pad, a capture band for capturing the analyte and at least one control band, or alternatively, the chromatographic strip contains the mobilizable detectable agent in place of a conjugate pad, where the test strip is configured to support removal of red blood cells from the sample and to allow uni-directional or bi-directional fluid flow of fluid from the sample filter to the capture band to be retained therein and detected thereon. | 04-22-2010 |
20120015429 | QUANTITATIVE LATERAL FLOW SYSTEM AND ASSAY - The present invention relates to a lateral flow assay and system, including a test strip, for detection and quantification of analytes in samples, such as samples containing cells and fluid. In general, according to the present invention, a test strip for a lateral flow assay for detection of at least one analyte in a sample comprises: (1) a chromatographic strip, a sample filter, a fluid-impermeable barrier, and means for providing a mobilizable detectable agent that is capable of binding to the at least one analyte or to the capture agent after capturing the analyte to the chromatographic strip such that the mobilizable detectable agent migrates through the chromatographic strip and contacts sample that has passed through the sample filter and also has migrated through the chromatographic strip. The test strip allows detection with or without quantitation of an analyte in a sample containing whole cells. | 01-19-2012 |
Patent application number | Description | Published |
20090198326 | ACCOMMODATIVE INTRAOCULAR LENS SYSTEM - An accommodative intraocular lens system for treating presbyopic is disclosed. The system includes a first lens having negative optic power adapted for placement in the posterior chamber of the eye and capable of moving forward and back along the optic axis; and a second lens having a positive optic power which is implanted within the capsular bag. The second lens can be the natural crystalline lens of the eye. The position of the first lens, forward or back relative to the second lens, focuses the eye for seeing distant or close-in objects. | 08-06-2009 |
20130103144 | SYSTEM FOR FORMING AND MODIFYING LENSES AND LENSES FORMED THEREBY - A lens for placement in a human eye, such as an intraocular lens, has at least some of its optical properties modified with a laser. The lens preferably contains at least 5% by weight UV absorber so commercially feasible rates of manufacture can be achieved. The laser forms modified loci in the lens where the modified loci have a different refractive index than the refractive index of the material before modification. The same laser modification technique can be used on the cornea in situ. | 04-25-2013 |
20140066946 | Preloaded Intraocular Lens (IOL) System and Method - A preloaded intraocular lens (IOL) system/method utilizing haptic compression is disclosed. The disclosed system/method utilizes an IOL packaged in a compressed state that is inserted into a patient using a cartridge and lumen through which the IOL is advanced. Within this context the haptics to the IOL are wrapped around the IOL in a coplanar fashion during the loading of the IOL to permit the IOL to be shipped and stored in a compressed state. This compressed state is achieve by wrapping the haptics of the IOL during the manufacturing process to ensure that the IOL is properly aligned and thus delivered in a predetermined orientation within the patient's eye. This compressed packaging of the IOL permits a more uniform and consistent placement of the IOL in the patient and eliminates the potential for physician error during the critical IOL placement procedure. | 03-06-2014 |
20140135920 | Hydrophilicity Alteration System and Method - A system/method allowing hydrophilicity alteration of a polymeric material (PM) is disclosed. The PM hydrophilicity alteration changes the PM characteristics by decreasing the PM refractive index, increasing the PM electrical conductivity, and increasing the PM weight. The system/method incorporates a laser radiation source that generates tightly focused laser pulses within a three-dimensional portion of the PM to affect these changes in PM properties. The system/method may be applied to the formation of customized intraocular lenses comprising material (PLM) wherein the lens created using the system/method is surgically positioned within the eye of the patient. The implanted lens refractive index may then be optionally altered in situ with laser pulses to change the optical properties of the implanted lens and thus achieve optimal corrected patient vision. This system/method permits numerous in situ modifications of an implanted lens as the patient's vision changes with age. | 05-15-2014 |
20140239524 | HYDROPHILICITY ALTERATION SYSTEM AND METHOD - A system/method allowing hydrophilicity alteration of a polymeric material (PM) is disclosed. The PM hydrophilicity alteration changes the PM characteristics by decreasing the PM refractive index, increasing the PM electrical conductivity, and increasing the PM weight. The system/method incorporates a laser radiation source that generates tightly focused laser pulses within a three-dimensional portion of the PM to affect these changes in PM properties. The system/method may be applied to the formation of customized intraocular lenses comprising material (PLM) wherein the lens created using the system/method is surgically positioned within the eye of the patient. The implanted lens refractive index may then be optionally altered in situ with laser pulses to change the optical properties of the implanted lens and thus achieve optimal corrected patient vision. This system/method permits numerous in situ modifications of an implanted lens as the patient's vision changes with age. | 08-28-2014 |
20140243443 | HYDROPHILICITY ALTERATION SYSTEM AND METHOD - A system/method allowing hydrophilicity alteration of a polymeric material (PM) is disclosed. The PM hydrophilicity alteration changes the PM characteristics by decreasing the PM refractive index, increasing the PM electrical conductivity, and increasing the PM weight. The system/method incorporates a laser radiation source that generates tightly focused laser pulses within a three-dimensional portion of the PM to affect these changes in PM properties. The system/method may be applied to the formation of customized intraocular lenses comprising material (PLM) wherein the lens created using the system/method is surgically positioned within the eye of the patient. The implanted lens refractive index may then be optionally altered in situ with laser pulses to change the optical properties of the implanted lens and thus achieve optimal corrected patient vision. This system/method permits numerous in situ modifications of an implanted lens as the patient's vision changes with age. | 08-28-2014 |
20140249516 | HYDROPHILICITY ALTERATION SYSTEM AND METHOD - A system/method allowing hydrophilicity alteration of a polymeric material (PM) is disclosed. The PM hydrophilicity alteration changes the PM characteristics by decreasing the PM refractive index, increasing the PM electrical conductivity, and increasing the PM weight. The system/method incorporates a laser radiation source that generates tightly focused laser pulses within a three-dimensional portion of the PM to affect these changes in PM properties. The system/method may be applied to the formation of customized intraocular lenses comprising material (PLM) wherein the lens created using the system/method is surgically positioned within the eye of the patient. The implanted lens refractive index may then be optionally altered in situ with laser pulses to change the optical properties of the implanted lens and thus achieve optimal corrected patient vision. This system/method permits numerous in situ modifications of an implanted lens as the patient's vision changes with age. | 09-04-2014 |
20140288644 | HYDROPHILICITY ALTERATION SYSTEM AND METHOD - A system/method allowing hydrophilicity alteration of a polymeric material (PM) is disclosed. The PM hydrophilicity alteration changes the PM characteristics by decreasing the PM refractive index, increasing the PM electrical conductivity, and increasing the PM weight. The system/method incorporates a laser radiation source that generates tightly focused laser pulses within a three-dimensional portion of the PM to affect these changes in PM properties. The system/method may be applied to the formation of customized intraocular lenses comprising material (PLM) wherein the lens created using the system/method is surgically positioned within the eye of the patient. The implanted lens refractive index may then be optionally altered in situ with laser pulses to change the optical properties of the implanted lens and thus achieve optimal corrected patient vision. This system/method permits numerous in situ modifications of an implanted lens as the patient's vision changes with age. | 09-25-2014 |
Patent application number | Description | Published |
20110183897 | VARIANT ACTIVIN RECEPTOR POLYPEPTIDES - The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided. | 07-28-2011 |
20120328595 | VARIANT ACTIVIN RECEPTOR POLYPEPTIDES AND USES THEREOF - The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided. | 12-27-2012 |
20130288983 | VARIANT ACTIVIN RECEPTOR POLYPEPTIDES AND USES THEREOF - The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided. | 10-31-2013 |
20140194355 | Isolated Nucleic Acid Molecules Encoding Variant Activin Receptor Polypeptides - The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided. | 07-10-2014 |
20140348827 | VARIANT ACTIVIN RECEPTOR POLYPEPTIDES, ALONE OR IN COMBINATION WITH CHEMOTHERAPY, AND USES THEREOF - The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided. | 11-27-2014 |
Patent application number | Description | Published |
20080255120 | SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES - The present invention relates to new substituted five-membered compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula: | 10-16-2008 |
20110136763 | TRISUBSTITUTED BORON-CONTAINING MOLECULES - This invention largely relates to 3,4,6-trisubstituted benzoxaborole compounds, and their use for treating bacterial infections. | 06-09-2011 |
20110166104 | BORON-CONTAINING SMALL MOLECULES - This invention provides, among other things, novel compounds useful for treating inflammatory conditions, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent. | 07-07-2011 |
20110172187 | BORON-CONTAINING SMALL MOLECULES - This invention relates to, among other items, 6-substituted benzoxaborole compounds and their use for treating bacterial infections. | 07-14-2011 |
20110207701 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS - This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent. | 08-25-2011 |
20110212918 | BORON-CONTAINING SMALL MOLECULES - This invention relates to, among other items, 6-substituted benzoxaborole compounds and their use for treating bacterial infections. | 09-01-2011 |
20120295875 | BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS - This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent. | 11-22-2012 |
20130131016 | BORON-CONTAINING SMALL MOLECULES - This invention provides novel compounds, methods of using the compounds, and pharmaceutical formulations comprising the compounds. | 05-23-2013 |
20130131017 | BORON-CONTAINING SMALL MOLECULES - This invention provides novel compounds, methods of using the compounds, and pharmaceutical compositions containing the compounds. | 05-23-2013 |
20150025038 | BORON-CONTAINING SMALL MOLECULES - This invention provides novel compounds, methods of using the compounds, and pharmaceutical formulations comprising the compounds. | 01-22-2015 |